HK57097A - Bivalent metal salts of 2-n,n-di(carboxymethyl) amino,3-cyano,4-carboxymethyl,5-carboxy-thiophene-acid, process for their preparation and pharmaceutical compositions containing them - Google Patents

Bivalent metal salts of 2-n,n-di(carboxymethyl) amino,3-cyano,4-carboxymethyl,5-carboxy-thiophene-acid, process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
HK57097A
HK57097A HK57097A HK57097A HK57097A HK 57097 A HK57097 A HK 57097A HK 57097 A HK57097 A HK 57097A HK 57097 A HK57097 A HK 57097A HK 57097 A HK57097 A HK 57097A
Authority
HK
Hong Kong
Prior art keywords
carboxymethyl
acid
amino
cyano
formula
Prior art date
Application number
HK57097A
Other languages
English (en)
French (fr)
Inventor
Wierzbicki Michel
Bonnet Jacqueline
Brisset Martine
Tsouderos Yannis
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HK57097A publication Critical patent/HK57097A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (7)

  1. Verfahren zur Herstellung von Salzen der Säure 2-N,N-Di(carboxymethyl)-amino-3-cyano-4-carboxymethyl-5-carboxy-thiophen mit zweiwertigen Metallen der allgemeinen Formel I: worin M ein zweiwertiges Metall, wie Strontium, Calcium oder Magnesium bedeutet, dadurch gekennzeichnet, daß man als Ausgangsmaterial den Tetraester der Formel II: verwendet, den man
    a) entweder in Gegenwart von Natriumhydroxid in wäßrig-alkoholischem Medium zum Sieden am Rückfluß erhitzt und dann in saurem Medium zur Bildung der Saure der Formel III: hydrolysiert, welche man in wäßrigem Medium mit dem Hydroxid der allgemeinen Formel (IV):         M(OH)₂   (IV) in der M die in Anspruch 1 angegebenen Bedeutungen besitzt, umsetzt;
    b) oder in einer 50/50 (Volumen)-Mischung aus einer 1n Natriumhydroxidlösung und Ethanol zum Sieden am Rückfluß erhitzt, so daß man nach dem Abdestllieren der Lösungsmittel das Tetranatriumsalz der Formel V erhält, welches man in wäßriger Lösung mit dem Chlorid der Formel VI:         MCl₂   (VI) in der M die in Anspruch 1 angegebenen Bedeutungen besitzt, behandelt; oder
    c) in wäßrig-alkoholischem Medium mit dem oben definierten Hydroxid der allgemeinen Formel IV zum Sieden am Rückfluß erhitzt.
  2. Verfahren nach Anspruch 1 zur Herstellung des Distrontiumsalzes der Säure 2-N,N-Di(carboxymethyl)-amino-3-cyano-4-carboxymethyl-5-carboxythiophen in Form des Octahydrats, Heptahydrats und Tetrahydrats.
  3. Verfahren zur Herstellung der Säure 2-N,N-Di(carboxymethyl)-amino-3-cyano-4-carboxymethyl-5-carboxy-thiophen, dadurch gekennzeichnet, daß man den in Anspruch 1 definierten Tetraester der Formel I in Gegenwart von Natriumhydroxid in wäßrig alkoholischem Medium zum Sieden am Rückfluß erhitzt und dann in saurem Medium hydrolysiert zur Bildung der Säure der in Anspruch 1 definierten Formel III, welche Säure ein neues Produkt ist, das als Synthesezwischenprodukt zur Herstellung der Salze der in Anspruch 1 definierten Formel I gemäß den Ansprüchen 1 und 2 verwendet werden kann.
HK57097A 1989-09-01 1997-05-01 Bivalent metal salts of 2-n,n-di(carboxymethyl) amino,3-cyano,4-carboxymethyl,5-carboxy-thiophene-acid, process for their preparation and pharmaceutical compositions containing them HK57097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911475A FR2651497B1 (fr) 1989-09-01 1989-09-01 Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Publications (1)

Publication Number Publication Date
HK57097A true HK57097A (en) 1997-05-09

Family

ID=9385063

Family Applications (1)

Application Number Title Priority Date Filing Date
HK57097A HK57097A (en) 1989-09-01 1997-05-01 Bivalent metal salts of 2-n,n-di(carboxymethyl) amino,3-cyano,4-carboxymethyl,5-carboxy-thiophene-acid, process for their preparation and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (1) US5128367A (de)
EP (1) EP0415850B1 (de)
JP (1) JPH0692386B2 (de)
AT (1) ATE100093T1 (de)
AU (1) AU624022B2 (de)
CA (1) CA2024419C (de)
DE (2) DE69005950T2 (de)
DK (1) DK0415850T3 (de)
ES (1) ES2062450T4 (de)
FR (1) FR2651497B1 (de)
HK (1) HK57097A (de)
IE (1) IE65157B1 (de)
LU (1) LU91125I2 (de)
NL (1) NL300168I2 (de)
NZ (1) NZ234770A (de)
OA (1) OA09463A (de)
PT (1) PT95184B (de)
ZA (1) ZA906716B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
PT1622630E (pt) 2003-05-07 2012-10-11 Osteologix As Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
US6905723B2 (en) * 2003-05-30 2005-06-14 Depuy Products, Inc. Strontium-substituted apatite coating
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
JP4954867B2 (ja) 2004-05-06 2012-06-20 オステオロジックス エイ／エス 有機金属塩類を製造するための高収率で迅速な合成法
DK1768748T4 (da) 2004-06-25 2019-06-11 Mokwalo Spf S A Sammensætninger omfattende strontium og vitamin D og anvendelser deraf
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN100391955C (zh) * 2005-04-30 2008-06-04 河北医科大学 一种雷尼酸锶中间体的合成方法
WO2007020527A2 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of strontium ranelate
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101229154B (zh) * 2007-01-26 2010-05-12 鲁南制药集团股份有限公司 治疗骨质疏松的药物组合物
FR2921367B1 (fr) * 2007-09-26 2009-10-30 Servier Lab Nouveau procede de synthese du ranelate de strontium et de ses hydrates
US20120123131A1 (en) * 2008-08-22 2012-05-17 Koilpillai Joseph Prabahar Process for the preparation of strontium ranelate
WO2010034806A1 (en) 2008-09-29 2010-04-01 Ratiopharm Gmbh Anhydrate and hydrate forms of strontium ranelate
CN101747316B (zh) * 2008-12-12 2013-09-25 重庆医药工业研究院有限责任公司 高纯度的雷奈酸锶及其制备方法
EP2416756A2 (de) 2009-04-10 2012-02-15 Mahmut Bilgic Stabile pharmazeutische zusammensetzungen mit hoher bioverfügbarkeit
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
CN101775002B (zh) * 2009-12-23 2015-07-15 浙江华海药业股份有限公司 一种制备雷尼酸锶的方法
HU228820B1 (en) 2010-01-14 2013-05-28 Richter Gedeon Nyrt Process for the preparation of distrontium ranelate
IT1398542B1 (it) * 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
WO2011110597A1 (de) 2010-03-11 2011-09-15 Azad Pharmaceutical Ingredients Ag Verfahren zur herstellung von strontiumranelat
WO2011124992A1 (en) 2010-03-24 2011-10-13 Actavis Group Ptc Ehf Substantially pure strontium ranelate
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012046251A2 (en) * 2010-10-08 2012-04-12 Glenmark Generics Limited Novel form of ranelic acid
CN102180864B (zh) * 2011-03-28 2012-12-12 中国药科大学 一种雷尼酸锶的制备方法
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
US9301945B2 (en) 2011-07-21 2016-04-05 Emory University Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (de) 2012-03-23 2013-09-25 Urquima S.A. Feste Formen von Strontiumranelat und Verfahren zu ihrer Herstellung
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate
CN103804345B (zh) * 2013-09-06 2017-03-15 精华制药集团股份有限公司 一种用hplc法中控制备高纯度雷尼酸锶的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905577A1 (de) * 1989-02-23 1990-08-30 Basf Ag Diaminothiophene

Also Published As

Publication number Publication date
AU6203390A (en) 1991-03-07
DE69005950T2 (de) 1994-07-21
LU91125I2 (fr) 2005-02-15
NZ234770A (en) 1991-11-26
IE65157B1 (en) 1995-10-04
EP0415850A1 (de) 1991-03-06
CA2024419A1 (fr) 1991-03-02
PT95184A (pt) 1991-05-22
EP0415850B1 (de) 1994-01-12
OA09463A (fr) 1992-11-15
DE69005950D1 (de) 1994-02-24
DE122005000001I2 (de) 2006-02-09
ES2062450T4 (es) 2011-12-29
FR2651497B1 (fr) 1991-10-25
CA2024419C (fr) 1999-07-20
ES2062450T3 (es) 1994-12-16
JPH0692386B2 (ja) 1994-11-16
PT95184B (pt) 1997-06-30
ZA906716B (en) 1991-06-26
DE122005000001I1 (de) 2005-05-12
IE903162A1 (en) 1991-03-13
FR2651497A1 (fr) 1991-03-08
ATE100093T1 (de) 1994-01-15
AU624022B2 (en) 1992-05-28
NL300168I1 (nl) 2005-03-01
JPH03169876A (ja) 1991-07-23
NL300168I2 (nl) 2005-03-01
US5128367A (en) 1992-07-07
DK0415850T3 (da) 1994-03-21

Similar Documents

Publication Publication Date Title
US5128367A (en) Divalent metal salts of 2-[N-N-di(carboxymethyl)amino]-3-cyano-4-carboxymethylthiophene-5-carboxylic acid
US5190947A (en) Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
US3067101A (en) Method for controlling hypertension
NZ198879A (en) Tetra substituted benzene derivatives and pharmaceutical compositions
US3452081A (en) Phenoxy substituted 2-alkenoic acids
US4450292A (en) Derivatives of phenyl aliphatic carboxylic acids, and use thereof in treating gastric and gastro-duodenal ailments
US4939164A (en) Strontium salt
SE463366B (sv) Anvaendning av substituerade 4-fenyl-4-oxo-2-butensyraderivat foer framstaellning av laekemedel foer behandling av sjukdomar i matsmaeltningskanalen och som antiulceroest laekemedel
US4594443A (en) Derivatives of 4-phenyl-4-oxo-buten-2-oic acid and therapeutic use thereof
GB2107714A (en) Phenyl ketones
US4867737A (en) Derivatives of 4-phenyl-4-oxo-2-butenoic acid their preparation process, their use as medicaments and compositions containing them
US4563477A (en) Process for the preparation of alpha-(N-pyrrolyl)-derivative acids, the salts and esters thereof; alpha-(N-pyrrolyl)-phenylacetic acids, the esters thereof, pharmaceutical compositions containing them and therapeutical applications thereof
WO2003099269A1 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
JPS6320426B2 (de)
JPS6324498B2 (de)
US3700675A (en) Ester of 2-hydroxy-cyclohexane-2-substituted carboxylic acids
JPH0323526B2 (de)
JPH0629184B2 (ja) 骨粗鬆症治療剤
JPS58170752A (ja) Ｎ−カルバモイルアミノ酸誘導体
HU207294B (en) Process for producing benzene-sulfonamide derivatives and pharmaceutical compositions containing them
IT9020483A1 (it) Derivato di idrossiprolina, sua preparazione e composizioni farmaceutiche che lo contengono
GB2162519A (en) New 4-oxo-2-butenoic acid derivatives
NO117370B (de)
JPS5844674B2 (ja) シンキチエノ−ピリジンユウドウタイノ セイゾウホウホウ
NO164532B (no) Analogifremgangsmaate for fremstilling av acetyldikarnitindiklorid.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100830